NLS Clinical Trials

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease, states the company.

BioInvent International has announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD’s anti-PD-1 therapy KEYTRUDA in patients with recurrent ovarian cancer who have progressed following platinum-based therapy.

Hemab Therapeutics has announced positive results from its completed Phase 2 multiple ascending dose (MAD) portion of the CL-101 study of sutacimig for the prophylactic treatment of Glanzmann thrombasthenia (GT).

Zelluna has announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances.